Medical management of hepatorenal syndrome

Nephrology Dialysis Transplantation

Volumn 27, Issue 1, 2012, Pages 34-41

  Davenport, Andrew ^a   Ahmad, Jawad ^b   Al Khafaji, Ali ^c   Kellum, John A ^c   Genyk, Yuri S ^d   Nadim, Mitra K ^e  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b MOUNT SINAI HOSPITAL   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

albumin; ascites; hepatorenal; vasopressors

Indexed keywords

ALBUMIN; MIDODRINE; NORADRENALIN; NORFLOXACIN; OCTREOTIDE; PENTOXIFYLLINE; TERLIPRESSIN; VASOPRESSIN;

ANTIBIOTIC PROPHYLAXIS; BACTERIAL PERITONITIS; BLOOD VOLUME; BOLUS INJECTION; CLINICAL PRACTICE; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RESPONSE; FLUID RESUSCITATION; HEPATORENAL SYNDROME; HUMAN; ISCHEMIA; KIDNEY DYSFUNCTION; LIVER CIRRHOSIS; PARACENTESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

DISEASE MANAGEMENT; HEPATORENAL SYNDROME; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PROGNOSIS; RENAL INSUFFICIENCY;

EID: 84856657285     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr736     Document Type: Review

References (84)

1. Arroyo V, Ginès P, Gerbes AL et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996; 23: 164-176 (Pubitemid 26012105)
2. Bataller R, Sort P, Ginès P et al. Hepatorenal syndrome: definition, pathophysiology, clinical features and management. Kidney Int Suppl 1998; 66: S47-S53
3. Salerno F, Gerbes A, Gines P et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007; 56: 1310-1318 (Pubitemid 47300435)
4. Gines P, Guevara M, Arroyo V et al. Hepatorenal syndrome. Lancet 2003; 362: 1819-1827 (Pubitemid 37494763)
5. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53: 397-417
6. Vella K, Goldfrad C, Rowan K et al. Use of consensus development to establish national research priorities in critical care. BMJ 2000; 320: 976-980 (Pubitemid 30192866)
7. Guyatt GH, Oxman AD, Kunz R et al. Going from evidence to recommendations. BMJ 2008; 336: 1049-1051
8. Atkins D, Best D, Briss PA et al. Grading quality of evidence and strength of recommendations. BMJ 2004; 328: 1490
9. Thabut D, Massard J, Gangloff A et al. Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure. Hepatology 2007; 46: 1872-1882
10. Fernandez J, Escorsell A, Zabalza M et al. Adrenal insufficiency in patients with cirrhosis and septic shock: effect of treatment with hy-drocortisone on survival. Hepatology 2006; 44: 1288-1295 (Pubitemid 44748379)
11. Boyer TD, Zia P, Reynolds TB. Effect of indomethacin and prosta-glandin A1 on renal function and plasma renin activity in alcoholic liver disease. Gastroenterology 1979; 77: 215-222 (Pubitemid 9206030)
12. Sural S, Sharma RK, Gupta A et al. Acute renal failure associated with liver disease in India: etiology and outcome. Ren Fail 2000; 22: 623-634
13. Albillos A, Lledo JL, Rossi I et al. Continuous prazosin administration in cirrhotic patients: effects on portal hemodynamics and on liver and renal function. Gastroenterology 1995; 109: 1257-1265
14. Gentilini P, Romanelli RG, La Villa G et al. Effects of low-dose captopril on renal hemodynamics and function in patients with cirrhosis of the liver. Gastroenterology 1993; 104: 588-594 (Pubitemid 23033435)
15. Llach J, Gines P, Arroyo V et al. Effect of dipyridamole on kidney function in cirrhosis. Hepatology 1993; 17: 59-64 (Pubitemid 23027385)
16. Hampel H, Bynum GD, Zamora E et al. Risk factors for the development of renal dysfunction in hospitalized patients with cirrhosis. Am J Gastroenterol 2001; 96: 2206-2210 (Pubitemid 32660919)
17. Guevara M, Fernandez-Esparrach G, Alessandria C et al. Effects of contrast media on renal function in patients with cirrhosis: a prospective study. Hepatology 2004; 40: 646-651 (Pubitemid 39265586)
18. Fernandez J, Navasa M, Planas R et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007; 133: 818-824 (Pubitemid 47374144)
19. Lebrec D, Thabut D, Oberti F et al. Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology 2010; 138: 1755-1762
20. Sort P, Navasa M, Arroyo V et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341: 403-409 (Pubitemid 29362513)
21. Abelmann WH. Hyperdynamic circulation in cirrhosis: a historical perspective. Hepatology 1994; 20: 1356-1358 (Pubitemid 24323588)
22. Marik PE, Baram M, Vahid B. Does central venous pressure predict fluid responsiveness? A systematic review of the literature and the tale of seven mares. Chest 2008; 134: 172-178
23. Osman D, Ridel C, Ray P et al. Cardiac filling pressures are not appropriate to predict hemodynamic response to volume challenge. Crit Care Med 2007; 35: 64-68 (Pubitemid 46035678)
24. Umgelter A, Reindl W, Wagner KS et al. Effects of plasma expansion with albumin and paracentesis on haemodynamics and kidney function in critically ill cirrhotic patients with tense ascites and hepatorenal syndrome: a prospective uncontrolled trial. Crit Care 2008; 12: R4
25. Marik PE, Cavallazzi R, Vasu T et al. Dynamic changes in arterial waveform derived variables and fluid responsiveness in mechanically ventilated patients: a systematic review of the literature. Crit Care Med 2009; 37: 2642-2647
26. Perner A, Faber T. Stroke volume variation does not predict fluid responsiveness in patients with septic shock on pressure support ventilation. Acta Anaesthesiol Scand 2006; 50: 1068-1073 (Pubitemid 44434744)
27. Mintz GS, Kotler MN, Parry WR et al. Reat-time inferior vena caval ultrasonography: normal and abnormal findings and its use in assessing right-heart function. Circulation 1981; 64: 1018-1025 (Pubitemid 11028101)
28. Diebel LN, Wilson RF, Tagett MG et al. End-diastolic volume. A better indicator of preload in the critically ill. Arch Surg 1992; 127: 817-821, discussion 821-822
29. Feissel M, Michard F, Mangin I et al. Respiratory changes in aortic blood velocity as an indicator of fluid responsiveness in ventilated patients with septic shock. Chest 2001; 119: 867-873 (Pubitemid 32197661)
30. Renner J, Meybohm P, Gruenewald M et al. Global end-diastolic volume during different loading conditions in a pediatric animal model. Anesth Analg 2007; 105: 1243-1249, table of contents (Pubitemid 350303925)
31. Charron C, Caille V, Jardin F et al. Echocardiographic measurement of fluid responsiveness. Curr Opin Crit Care 2006; 12: 249-254 (Pubitemid 44365954)
32. Andreu V, Perello A, Moitinho E et al. Total effective vascular compliance in patients with cirrhosis. Effects of propranolol. J Hepatol 2002; 36: 356-361 (Pubitemid 34194795)
33. Fernandez J, Monteagudo J, Bargallo X et al. A randomized un-blinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology 2005; 42: 627-634 (Pubitemid 41233655)
34. Angeli P, Volpin R, Gerunda G et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hep-atology 1999; 29: 1690-1697 (Pubitemid 29247040)
35. Esrailian E, Pantangco ER, Kyulo NL et al. Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci 2007; 52: 742-748
36. Duvoux C, Zanditenas D, Hezode C et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology 2002; 36: 374-380 (Pubitemid 34810356)
37. Ortega R, Gines P, Uriz J et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002; 36: 941-948
38. Ruiz-del-Arbol L, Monescillo A, Arocena C et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005; 42: 439-447 (Pubitemid 41061097)
39. Gines P, Tito L, Arroyo V et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988; 94: 1493-1502
40. Gines P, Arroyo V, Quintero E et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. Gastroenterology 1987; 93: 234-241 (Pubitemid 17097585)
41. Pozzi M, Osculati G, Boari G et al. Time course of circulatory and humoral effects of rapid total paracentesis in cirrhotic patients with tense, refractory ascites. Gastroenterology 1994; 106: 709-719 (Pubitemid 24064339)
42. Shear W, Rosner MH. Acute kidney dysfunction secondary to the abdominal compartment syndrome. J Nephrol 2006; 19: 556-565 (Pubitemid 46415917)
43. Dalfino L, Tullo L, Donadio I et al. Intra-abdominal hypertension and acute renal failure in critically ill patients. Intensive Care Med 2008; 34: 707-713 (Pubitemid 351660087)
44. Savino JA, Cerabona T, Agarwal N et al. Manipulation of ascitic fluid pressure in cirrhotics to optimize hemodynamic and renal function. Ann Surg 1988; 208: 504-511 (Pubitemid 18266466)
45. Umgelter A, Reindl W, Franzen M et al. Renal resistive index and renal function before and after paracentesis in patients with hepatorenal syndrome and tense ascites. Intensive Care Med 2009; 35: 152-156
46. Hadengue A, Gadano A, Moreau R et al. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 1998; 29: 565-570 (Pubitemid 28484945)
47. Uriz J, Gines P, Cardenas A et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000; 33: 43-48 (Pubitemid 30418933)
48. Duhamel C, Mauillon J, Berkelmans I et al. Hepatorenal syndrome in cirrhotic patients: terlipressine is a safe and efficient treatment; propranolol and digitalic treatments: precipitating and preventing factors? Am J Gastroenterol 2000; 95: 2984-2985
49. Mulkay JP, Louis H, Donckier V et al. Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study. Acta Gastroenterol Belg 2001; 64: 15-19 (Pubitemid 32291099)
50. Colle I, Durand F, Pessione F et al. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with terlipressin: a retrospective analysis. J Gastroen-terol Hepatol 2002; 17: 882-888
51. Moreau R, Durand F, Poynard T et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002; 122: 923-930 (Pubitemid 34267275)
52. Halimi C, Bonnard P, Bernard B et al. Effect of terlipressin (Glypres-sin) on hepatorenal syndrome in cirrhotic patients: results of a multi-centre pilot study. Eur J Gastroenterol Hepatol 2002; 14: 153-158 (Pubitemid 34163994)
53. Danalioglu A, Cakaloglu Y, Karaca C et al. Terlipressin and albumin combination treatment in hepatorenal syndrome. Hepatogastroenter-ology 2003; 50 (Suppl 2): ccciii-cccv
54. Solanki P, Chawla A, Garg R et al. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 2003; 18: 152-156 (Pubitemid 36349860)
55. Alessandria C, Ottobrelli A, Debernardi-Venon W et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol 2007; 47: 499-505 (Pubitemid 47331744)
56. Sharma P, Kumar A, Shrama BC et al. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol 2008; 103: 1689-1697
57. Neri S, Pulvirenti D, Malaguarnera M et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Dig Dis Sci 2008; 53: 830-835 (Pubitemid 351317073)
58. Sanyal AJ, Boyer T, Garcia-Tsao G et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepa-torenal syndrome. Gastroenterology 2008; 134: 1360-1368 (Pubitemid 351615358)
59. Martin-Llahi M, Pepin MN, Guevara M et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008; 134: 1352-1359 (Pubitemid 351626950)
60. Testro AG, Wongseelashote S, Angus PW et al. Long-term outcome of patients treated with terlipressin for types 1 and 2 hepatorenal syndrome. J Gastroenterol Hepatol 2008; 23: 1535-1540
61. Tandon P, Tsuyuki RT, Mitchell L et al. The effect of 1 month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot study. Liver Int 2009; 29: 169-174
62. Skagen C, Einstein M, Lucey MR et al. Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome. J Clin Gastroenterol 2009; 43: 680-685
63. Kiser TH, Fish DN, Obritsch MD et al. Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study. Nephrol Dial Transplant 2005; 20: 1813-1820 (Pubitemid 41222593)
64. Gluud LL, Christensen K, Christensen E et al. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology 2010; 51: 576-584
65. Gluud LL, Christensen K, Christensen E et al. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology 2010; 51: 576-584
66. Kiser TH, Maclaren R, Fish DN. Treatment of hepatorenal syndrome. Pharmacotherapy 2009; 29: 1196-211
67. Moller S, Bendtsen F, Henriksen JH. Pathophysiological basis of pharmacotherapy in the hepatorenal syndrome. Scand J Gastroenterol 2005; 40: 491-500 (Pubitemid 40676241)
68. Davenport A. The brain and the kidney-organ cross talk and interactions. Blood Purif 2008; 26: 526-536
69. Krag A, Moller S, Henriksen JH et al. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome. Hepatology 2007; 46: 1863-1871
70. Eefsen M, Dethloff T, Frederiksen HJ et al. Comparison of terlipressin and noradrenalin on cerebral perfusion, intracranial pressure and cerebral extracellular concentrations of lactate and pyruvate in patients with acute liver failure in need of inotropic support. J Hepatol 2007; 47: 381-386 (Pubitemid 47189608)
71. Pomier-Layrargues G, Paquin SC, Hassoun Z et al. Octreotide in hep-atorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. Hepatology 2003; 38: 238-243
72. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004; 40: 55-64 (Pubitemid 38868923)
73. Guevara M, Gines P, Fernandez-Esparrach G et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998; 27: 35-41 (Pubitemid 28041531)
74. Gulberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hep-atology 1999; 30: 870-875 (Pubitemid 29458273)
75. Bennett WM, Keeffe E, Melnyk C et al. Response to dopamine hydro-chloride in the hepatorenal syndrome. Arch Intern Med 1975; 135: 964-971
76. Gines A, Salmeron JM, Gines P et al. Oral misoprostol or intravenous prostaglandin E2 do not improve renal function in patients with cirrhosis and ascites with hyponatremia or renal failure. J Hepatol 1993; 17: 220-226 (Pubitemid 23054491)
77. Brenard R, Moreau R, Pussard E et al. Hemodynamic and sympathetic responses to human atrial natriuretic peptide infusion in patients with cirrhosis. J Hepatol 1992; 14: 347-356
78. Gadano A, Moreau R, Vachiery F et al. Natriuretic response to the combination of atrial natriuretic peptide and terlipressin in patients with cirrhosis and refractory ascites. J Hepatol 1997; 26: 1229-1234 (Pubitemid 27346634)
79. Wong F, Moore K, Dingemanse J et al. Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome. Hepatology 2008; 47: 160-168 (Pubitemid 351171053)
80. Holt S, Goodier D, Marley R et al. Improvement in renal function in hepatorenal syndrome with N-acetylcysteine. Lancet 1999; 353: 294-295 (Pubitemid 29088129)
81. Izzedine H, Kheder-Elfekih R, Deray G et al. Endothelin-receptor antagonist/N-acetylcysteine combination in type 1 hepatorenal syndrome. J Hepatol 2009; 50: 1055-1056
82. Akriviadis E, Botla R, Briggs W et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 1637-1648 (Pubitemid 32198689)
83. De BK, Gangopadhyay S, Dutta D et al. Pentoxifylline versus pre-dnisolone for severe alcoholic hepatitis: a randomized controlled trial. World J Gastroenterol 2009; 15: 1613-1619
84. Nazar A, Pereira GH, Guevara M et al. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2010; 51: 219-226